Lymphocytic colitis
diseaseOn this page
Summary
Lymphocytic colitis (MONDO:0000704) is a disease and 5 clinical trials. Top therapeutic interventions include budesonide and mesalamine. A subtype of microscopic colitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | lymphocytic colitis |
| Mondo ID | MONDO:0000704 |
| EFO | EFO:1001294 |
| MeSH | D046730 |
| Orphanet | 65279 |
| DOID | DOID:0060184 |
| ICD-10-CM | K52.832 |
| ICD-11 | 1629251056 |
| NCIT | C27147 |
| SNOMED CT | 31437008 |
| UMLS | C0400822 |
| MedGen | 98006 |
| MedDRA | 10025268 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of microscopic colitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › gastroenteritis › colitis › microscopic colitis › lymphocytic colitis
Related subtypes (2): collagenous colitis, eosinophilic colitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Budesonide | Phase 3 (in late-stage trials) |
| Mesalamine | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00217022 | PHASE2/PHASE3 | TERMINATED | Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis |
| NCT01209208 | PHASE3 | COMPLETED | Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis |
| NCT01504048 | Not specified | UNKNOWN | Usefulness of Chromoendoscopy in Diagnosing Microscopic Colitis |
| NCT01928667 | Not specified | COMPLETED | Case-Control Study to Identify Risk Factors for Microscopic Colitis |
| NCT05579444 | Not specified | TERMINATED | Systems Biology of Gastrointestinal and Related Diseases |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BUDESONIDE | 4 | 2 |
| MESALAMINE | 4 | 1 |
| CHEMBL249466 | 0 | 1 |
Related Atlas pages
- Drugs: Budesonide, Mesalamine